Abstract. Increasing number of microRNAs (miRNAs) have been reported to play an important role in the development and progression of non-small cell lung cancer (NSCLC). In particular, microRNA-497-5p (miR-497-5p) has been proposed as a tumor suppressor miRNA in human cancers. However, the role of miR-497-5p and its potential molecular mechanism associated with NSCLC are less studied. Therefore, the role of miR-497-5p in the pathogenesis of NSCLC was investigated. In the present study, the expression of miR-497-5p was significantly downregulated in NSCLC. Moreover, overexpression of miR-497-5p inhibited the proliferation and invasion of NSCLC cells by suppressing FGF2. In addition, FGF2 was a downstream target of miR-497-5p in NSCLC. FGF2 was upregulated in NSCLC promoting cell proliferation and invasion. Overexpression of FGF2 impaired the inhibitory effect of miR-497-5p in NSCLC. Taken together, these results demonstrate that miR-497-5p is a tumor suppressor miRNA and demonstrate its potential for future use in the treatment of human NSCLC.
Introduction
Lung cancer is one of the most common malignant tumors in the world and has become a major cause of high mortality in China's urban population (1) . Primary lung cancer includes small cell lung carcinoma (SCLC) and non-SCLC (NSCLC), and NSCLC accounts for ~85% of all lung cancer cases (2) . Although treatments have improved significantly in recent years, the prognosis of patients with NSCLC remains poor, with a 5-year survival rate of only ~16% (3) . Survival rates have been found to be closely associated with the lung cancer stage. Patients with stage I-III NSCLC can be treated surgically with a 5-year survival rate of 25-80% (4) . Stage IV patients with NSCLC are often treated by chemotherapy to relieve symptoms. Even so, patients with stage IV NSCLC have a poor prognosis with a 5-year survival rate of only 2% (5) . Unfortunately, NSCLC is often diagnosed in advanced stage. Therefore, finding effective screening strategies for early diagnosis is necessary. It would likely significantly reduce the morbidity and mortality of NSCLC.
It has been reported that microRNAs (miRNAs) inhibit expression of target genes by disrupting genes or impeding translation of mRNA (6) . Especially, increased microRNAs have been identified as lung cancer biomarkers (7) . For example, miR-215 inhibited the progression of NSCLC through targeting MMP-16 (8) . Wei and Ran (9) reported that miR-20a promoted proliferation and invasion by directly targeting EGR2 in NSCLC. Recently, the specific function of miR-497 has attracted our attention. It was proven that miR-497 can be used as an effective biomarker to diagnose and predict prognosis of osteosarcoma (10) . Abnormal expression and function of miR-497 have been identified in various types of human of cancer. For instance, miR-497 was downregulated and suppressed the development of renal cell carcinoma through targeting VEGFR-2 (11). Wu et al (12) proposed that miR-497 inhibited proliferation and induced apoptosis via the Bcl-2/ Bax-caspase-9-caspase-3 pathway in HUVECs. It was also reported that miR-497 accelerated apoptosis of cervical cancer cells through negatively regulating the MAPK/ERK signaling pathway (13) . However, it has been reported that miR-497 can also express high and enhanced metastasis by inhibiting SMAD7 in oral squamous cell carcinoma (14) . These results led us to further explore the role of miR-497-5p in NSCLC.
As a member of FGF family, fibroblast growth factor 2 (FGF2) is involved in mitogenic and proliferative effect (15) . FGF2 was reported to be upregulated in breast cancer and mediated cell migration and invasion (16) . Moreover, FGF2 was found to facilitate cell invasion in pancreatic cancer (17) . Joy et al (18) demonstrated that FGF2 could promote cell proliferation in human astrocytes and glioma. As a biomarker, FGF2 can predict the prognosis of patients with glioma (19) . In addition, the interaction between miRNAs and FGF2 has been reported in human cancers, such as miR- 15-16 (20) . However, the regulatory mechanism between miR-497-5p and FGF2 is unclear and an in-depth study is desired urgently in NSCLC. In the present study, the expression of miR-497-5p and its regulatory mechanism in NSCLC were investigated. Moreover, the relationship between miR-497-5p and FGF2 was also explored in NSCLC.
MicroRNA-497-5p inhibits proliferation and invasion
of non-small cell lung cancer by regulating FGF2 Cell transfection. miR-497-5p mimic and inhibitor were used to mimic and inhibit miR-497-5p expression. FGF2 siRNA was used to inhibit FGF2 expression. miR-497-5p mimic and inhibitor, and FGF2 siRNA (si-FGF2) were obtained from Shanghai GenePharma Co., Ltd. (Shanghai, China). They were then transferred to A549 cells with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) based on the manufacturer's protocols.
Cell proliferation. Cell proliferation was measured by the CCK-8 assay based on the manufacturer's instructions. First, 4x10 4 cells were plated and incubated in 96-well plates for 0, 24, 48 and 72 h. They were placed in an incubator with 5% CO 2 at 37˚C. Next, 10 µl of CCK-8 reagent was added to each well for 2 h (Dojindo Laboratories, Kumamoto, Japan). Finally, they were detected using a microplate reader (Molecular Devices LLC, Sunnyvale, CA, USA) at an absorbance of 450 nm. ). The overall survival was analyzed by the Kaplan-Meier method and the log rank test. Significant differences were defined as P<0.05.
Results

Downregulation of miR-497-5p identified in NSCLC tissues
and cell lines. First, mRNA expression of miR-497-5p was observed in NSCLC tissues. Downregulation of miR-497-5p was detected in NSCLC tissues compared to adjacent normal tissues (Fig. 1A) . In the NSCLC cell lines, downregulation of miR-497-5p was also identified. The expression levels of miR-497-5p were significantly decreased in the H1299, A549 and SPC-A1 cell lines compared to BEAS-2B cells (Fig. 1B) . In addition, the relationship between miR-497-5p abnormal expression and clinicopathological features of NSCLC patients was analyzed. Based on the expression of miR-497-5p, these cases were divided into a high miR-497-5p expression group and a low expression group, based on the median value of miR-497-5p expression levels in NSCLC patients as a cut-off point. We found that low miR-497-5p expression was associated with TNM stage (P=0.018) and distant metastases (P=0.02; Table I ). Besides, low miR-497-5p expression predicted a poor prognosis, with NSCLC patients having a shorter overall survival (P=0.0078; Fig. 1C ). Based on these results, we suspected that miR-497-5p was involved in the tumorigenesis of NSCLC.
Overexpression of miR-497-5p inhibited cell proliferation and invasion in NSCLC.
Next, miR-497-5p mimics or inhibitor was transfected into A549 cells to explore its role in NSCLC. The miR-497-5p mimics were found to enhance miR-497-5p expression ( Fig. 2A) and miR-497-5p inhibitor reduced its expression (Fig. 2B) . The ability of cell proliferation was then measured in transfected A549 cells. The CCK-8 assay indicated that upregulation of miR-497-5p suppressed proliferation of A549 cells (Fig. 2C) . In contrast, knockdown of miR-497-5p promoted cell proliferation in NSCLC cells (Fig. 2D) . In addition, the same effect of miR-497-5p was identified for cell invasion in NSCLC. miR-497-5p mimics significantly impaired cell invasive ability, while miR-497-5p inhibitor promoted invasion of A549 cells (Fig. 2E) . Therefore, overexpression of miR-497-5p was found to suppress cell proliferation and invasion in NSCLC.
FGF2 is a downstream target of miR-497-5p in NSCLC.
TargetScan (http://www.targetscan.org) was used to search for potential binding sites of the theoretical target gene with miR-497-5p. Among the predicted targets, the FGF2 gene was selected for further analysis because of its vital role in promoting tumor progression. The prediction of TargetScan showed that miR-497-5p had a binding site to the 3'UTR of FGF2 (Fig. 3A) . Luciferase assay was then performed to confirm the above prediction. The results showed that the miR-497-5p mimics significantly reduced the luciferase activity of wild-type FGF2. However, the luciferase activity of the mutant type FGF2 was not affected by the miR-497-5p mimics (Fig. 3B) . In addition, a negative correlation between miR-497-5p and FGF2 expression was identified in NSCLC tissues (P<0.0001, R 2 = 0.5738, Fig. 3C ). To further confirm the relationship between them, the expression of FGF2 was detected in A549 cells with miR-497-5p mimics or inhibitor. The results indicated that miR-497-5p mimics obviously suppressed FGF2 expression, while the miR-497-5p inhibitor enhanced the expression level of FGF2 ( Fig. 3D and E) . FGF2 is a direct target of miR-497-5p, and miR-497-5p negatively regulated FGF2 expression in NSCLC.
Upregulation of FGF2 promotes cell proliferation and invasion in NSCLC.
Then, FGF2 was identified to be upregulated in Table I . Relationship between miR-497-5p expression and the clinicopathological characteristics of NSCLC patients. NSCLC tissues (Fig. 4A and B) and H1299, A549 and SPC-A1 cell lines (Fig. 4C) . Moreover, high FGF2 expression was associated with TNM stage (P=0.009) and distant metastases (P=0.02; Table II) . Next, the effect of FGF2 was investigated in NSCLC by transfecting FGF2 siRNA in A549 cells. First, we found that FGF2 siRNA apparently reduced the expression of FGF2 (Fig. 4D) . Moreover, silencing of FGF2 prevented proliferation of A549 cells (Fig. 4E) . Similarly, knockdown of FGF2 also inhibited cell invasion in A549 cells (Fig. 4F ). In conclusion, it was confirmed that FGF2 functions as an oncogene in NSCLC by promoting cell proliferation and invasion.
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Upregulation of FGF2 impairs the inhibitory action of miR-497-5p in NSCLC.
Finally, the interaction between miR-497-5p and FGF2 was explored through co-transfecting the miR-497-5p mimics and the FGF2 vector into A549 cells. A decrease in FGF2 expression induced by the miR-497-5p mimics was found to be restored by the FGF2 vector (Fig. 5A) . Functionally, the CCK-8 assay indicated that upregulation of FGF2 impaired the inhibitory effect of miR-497-5p on cell proliferation in NSCLC (Fig. 5B) . Moreover, the inhibitory effect of miR-497-5p on cell invasion was also reversed by upregulation of FGF2 in A549 cells (Fig. 5C ). In conclusion, overexpression of FGF2 impaired the suppressive effect of miR-497-5p in NSCLC.
Discussion
Various microRNAs (miRNAs) that can assess the risk of tumor progression and metastasis have been reported for use in non-small cell lung cancer (NSCLC) (22) (23) (24) . In the present study, the expression of miR-497-5p was significantly reduced, and low expression of miR-497-5p was closely related to TNM stage and distant metastases of NSCLC. Similarly, miR-497 was reported to be downregulated and to inhibit tumor growth in NSCLC (25) , which was consistent with our results. Besides, downregulation of miR-497 was also observed in osteosarcoma (26) , thyroid (27) and colorectal cancer (28) . These findings suggest that abnormal miR-497-5p expression is involved in the pathogenesis of NSCLC.
The effect of miR-497-5p on cell proliferation and invasion was also investigated in NSCLC. Li et al demonstrated that overexpression of miR-497 suppressed cell proliferation and invasion in human retinoblastoma (29) . Similar inhibition of cell proliferation and invasion by miR-497-5p was also detected in NSCLC. Moreover, miR-497 has been found to regulate several target genes to mediate the development of human cancers. For example, miR-497 inhibited proliferation of hepatocellular carcinoma cells and induced cell apoptosis through targeting YAP1 (30). Ruan et al proposed that miR-497 inhibited proliferation, migration, and invasion of osteosarcoma cells via targeting AMOT (31) . In the present study, FGF2 was shown to be a downstream and direct target of miR-497-5p in NSCLC.
Subsequently, the alteration of FGF2 expression and its effects were investigated, and the regulation mechanism of miR-497-5p in NSCLC was further elucidated. Upregulation of FGF2 was identified in NSCLC, which promoted proliferation and invasion of NSCLC cells. Similarly to our results, Cheng et al demonstrated that FGF2 expression was increased and knockdown of FGF2 inhibited proliferation and invasion of NSCLC cells (32) . Besides, a negative correlation between miR-497-5p and FGF2 expression was revealed in NSCLC tissues. In addition, upregulation of FGF2 impaired the inhibitory effect of miR-497-5p in NSCLC. Similarly, previous studies have also shown that many miRNAs negatively regulated FGF2 expression, such as miR-195 (33), miR-205 (34) and miR-646 (35) . Moreover, He et al implied that miR-16 targeting FGF2 inhibited proliferation and invasion of nasopharyngeal carcinoma cells (36) . In the present study, miR-497-5p also inhibited proliferation and invasion of NSCLC cells by targeting FGF2.
In conclusion, in the present study, we revealed the inhibitory effect of miR-497-5p on the progression of NSCLC through targeting FGF2. This suggests that miR-497-5p acts as a novel tumor suppressor in NSCLC. In addition, FGF2 was a downstream target of miR-497-5p in NSCLC, indicating that FGF2 was involved in the regulatory mechanism of miR-497-5p. Further research is needed to investigate whether miR-497-5p is a useful biomarker and therapeutic target for NSCLC progression.
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